Weighing Options for First-Line Therapy in EGFR-Mutated NSCLC

(MedPage Today) — The selection of a first-line treatment for patients with advanced EGFR-positive non-small cell lung cancer (NSCLC) has become increasingly complex in recent years with available options now including osimertinib (Tagrisso, as…